Pfenex, BARDA Extends Anthrax Vaccine Pact - - BioPharm International

ADVERTISEMENT

Pfenex, BARDA Extends Anthrax Vaccine Pact



Pfenex, a biotechnology company offering recombinant protein expression, and the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), have modified its prime contract and exercised an option associated with their existing contractual relationship that began in July 2010. This modified agreement extends the prime contract and increases the funding to support the development of a recombinant protective antigen (rPA)-based anthrax vaccine based on rPA produced in the company’s platform technology, Pfēnex Expression Technology.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised.

During the contract’s base period, Pfenex demonstrated that a strongly immunogenic, stable, and protective form of rPA could be expressed and recovered from the fermentation of a strain of P. fluorescens engineered to produce rPA. The exercise of this option allows for the completion of preclinical studies, implementation of analytical methods, and cGMP manufacturing.

Source: Pfenex

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

First Biosimilar Application Kicks Off Legal Battle
October 31, 2014
FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Amgen, Sanofi, and Ono Pharmaceuticals Partner with Universities on Transmembrane Protein Research
October 28, 2014
Author Guidelines

Click here